Viamet discovers and develops "best-in-class" inhibitors of metalloenzymes via an innovative and proprietary platform, called the Metallophile^® Technology. The Metallophile Technology is based on our world-class expertise in bioinorganic chemistry and an extensive understanding of metalloenzyme structure and function. Using the Metallophile Technology, we can rapidly and cost-effectively generate best-in-class, patentable, small molecule inhibitors of metalloenzymes by optimizing the metal-binding component of existing compounds. The Metallophile Technology has enabled Viamet to rapidly build a portfolio of proprietary clinical compounds and drug candidates which address significant unmet medical needs and represent blockbuster commercial potential.